Determination of Emamectin Benzoate and Other Avermectin Residues In

Total Page:16

File Type:pdf, Size:1020Kb

Determination of Emamectin Benzoate and Other Avermectin Residues In DeterminationDetermination ofof EmamectinEmamectin BenzoateBenzoate andand otherother AvermectinAvermectin ResiduesResidues inin FishFish TissuesTissues UsingUsing LC/MSLC/MS Dayue Shang, Angelo Di Cicco, Nicole Gibbons, Monica Dyck and Helen Nicolidakis Health Canada, HPFB, Western Region Laboratory, Burnaby, B.C. V5G 4P2 AvermectinsAvermectins z What are they? z A group of compounds used as acaricides or parasiticides for animals or plants. z In aquaculture – emamectin and ivermectin are used to control sea lice in farmed salmon and trout. TheThe SeaSea LiceLice IssueIssue z Sea lice produce larvae which attach to salmon and feed on blood and mucous, causing serious damage and death to fish. z Farmed fish in unnatural and crowded conditions may lead to more sea lice, which could have an impact on wild salmon. z Ivermectin has been approved by VDD to treat sea lice infestation. Emamectin is still being evaluated by VDD, but can be used under the Emergency Drug Release program on a case by case basis. z Human health and environmental impacts are being investigated. z CFIA conducts routine tests of about 100 samples per year. HealthHealth Canada’sCanada’s ConcernConcern z Health Canada’s concerns around avermectins: z Accumulation of residues over time z Long term effects, especially in people whose diet consists of considerable fish consumption z Effects on most vulnerable individuals, e.g. children and people with compromised immune systems ChemicalChemical StructuresStructures OCH3 OCH3 N HO H3C OCH3 OCH3 O O H3C O H3C O CH3 CH3 H H CH3 CH3 H H O O O O H3C O CH3 H3C O CH H O H 3 H H O H3C R H H3C R O O Emamectin O O Abamectin OH H B1a, R=C2H5 OH H B1b, R=CH3 B1a, R=C2H5 O CH3 B1b, R=CH3 H O OH CH3 H OH OCH3 HO OCH3 O O CH3 CH3 H3C H H O O O CH3 H C 3 H O H H R H3C O O Ivermectin OH H B1a, R=C2H5 O B1b, R=CH3 CH3 H OH ChemicalChemical StructuresStructures H3CO N CH3 CH3 H O CH3 OCH O 3 H HO H3C CH3 CH3 OCH 3 O O O H C O 3 CH3 CH3 OH H H H O O H3C O H O Moxidectin H O H3C CH3 H O O OH OH H Doramectin OCH3 H O H3C N CH3 OCH3 H OH O O O CH3 H3C H H O O O CH3 H3C O H H H R H3C Eprinomectin O O OH H B1a, R=C2H5 B1b, R=CH3 O CH3 H OH AvermectinsAvermectins z Some characteristics: z Very hydrophobic z Low toxicity z Unknown cumulative effects SampleSample PreparationPreparation z Urgent need to develop a so-called “universal” sample preparation method for emergency situations. z More than two-thirds of the analysis time is spent on sample preparation. z Approximately 30% of the analytical error stems from the sample preparation step. z Optimizing the sample preparation procedure is crucial to the development of robust, reproducible, and accurate analytical methods. MythMyth No.No. 1:1: SPESPE cleanclean--upup andand concentrationconcentration isis alwaysalways neededneeded forfor aa goodgood LC/MS/MSLC/MS/MS methodmethod z Fact: an SPE cartridge normally has 3 to 5 plates while a HPLC column has a plate number of about 10,000. z Fact: it is often simply too much for a small SPE column to deal with the demand of a multi-residue method. z Solution: avoid SPE as much as possible when developing a multi-residue method. Instead, use a solvent removal unit to concentrate samples, followed by a good chromatographic separation. MythMyth No.No. 22:: OnlyOnly ASE,ASE, MSE,MSE, SFE,SFE, etc.etc. cancan efficientlyefficiently extractextract analytesanalytes fromfrom solidsolid matricesmatrices z Fact: many of the new apparatus require elaborate preparation steps, e.g. packing of 24 columns for ASE process. z Fact: tubing and re-used cartridges are potential sources of cross contamination. z Solution: design a method to test multiple solvents to find a good solvent system for the job. For trace analysis, disposable containers are recommended for sample preparation. AA reviewreview ofof samplesample preparationpreparation techniquestechniques z From several review papers, the techniques used for the detection of over 100 pharmaceutical compounds in biological and environment matrices (100% = all cases): z 98 % liquid-liquid (L-L) z 77 % protein precipitation z 45 % SPE z 26 % on-line and automated SPE z 8 % MSPE z 3 % ASE z 2 % Microwave z 1 % Other (MSPD, SFE, etc) z Your best bet: --------- MythMyth No.No. 33:: LiquidLiquid--liquidliquid extractionextraction hashas limitedlimited useuse whenwhen dealingdealing withwith solidsolid matricesmatrices z Fact: solid matrices usually can be liquefied with the help of homogenizers, and liquid samples may be laden with solid particulates. z Fact: L-L has been used in the determination of trace organics in solid samples for many years, eg. PCBs and Dioxins. z Solution: design a method to test multiple solvents and buffers to find a good solvent system; miniaturize the L-L process using disposable centrifuge tubes. FactorsFactors toto considerconsider inin developingdeveloping aa LL--LL extractionextraction methodmethod z All these factors have to be considered together: z Distribution coefficient z Solvent miscibility z pH adjustment z Temperature z Fatty substance z Solvent toxicity z Agitation z Solvent removal AA SystematicSystematic ApproachApproach Rapid Optimization Procedure for Extraction Method (Flowchart No. 2) (To be used in conjunction with Flowcharts no. 1 and 3) If matrix Add 10 ml of hexane, is oily rotate, freeze, and Polytron the samples at 1600 Divide the samples into 2 groups of 4. discard organic layer Spike 0.5 ml of 1 Add 20 ml of rpm for 30 sec. Add 0.5 ml of selected buffer to each before adding MTBE. Prepare Weigh out 5 g of ppm standard 0.01M EDTA Wash the polytron generator sample in Group 1, according to the START standards blank matrix into mixture and 0.5 (up to the 25 probe in a 400 ml beaker results outlined in flowchart no. 1. and 8 - 50 ml ml of 1 ppm IS ml mark) to containing a solution of 50% Similarily prepare group 2 with another solvents. centrifuge tubes. into each of the 8 each of the IPA and 1% formic acid. selected buffer. Usually one buffer for Add approx. 15 ml of samples. 16 samples. (Replace solution after every 5 acidic coompounds and the other for Ethyl acetate to the 40 samples). neutral and basic. If matrix ml mark. is not oily Cap the sample. Add 100 ul of Sonicate at Take the samples out Decant the organic layer to Make volume to 2 ml Vortex for 30sec. until all the Centrifuge Put the samples into diethylene glycol as a Filter with 13 35o C for and put into a tray with clean and labelled 15 ml with 10 mM NH OAc/ particulates are suspended. for 6 min. the - 80o C freezer for keeper. 4 mm Acrodisc 20 min. ice on the bottom. Wait centrifuge tubes. Make up with 100 uM disodium Use a disposable spatula to at 5350 25 min. (until aqueous Evaporate off the GHP filters Vortex for for 5 min. until the to 12 ml. Place them in EDTA. Vortex for 10 disturb the solid bed if the rpm. layer is frozen. organic layer (~ 25 (small purple). 30 sec. organic layer is clear. the vacuum centrifuge. sec. particulates are not min.). suspended. Add 1 ml of D.I. water to 0.5 ml IS Save the aqueous solution at Phase 3: Go to and 0.5 ml of STD mix to make a -20o C for future use. Flowchart No. 3 solvent standard. Spike 2 series of Make volume to 2 Set up the sample and Process the If results are Extract with the samples of 4, each with ml with 10mM run the sequence for data and END of accepable, START of selected buffersand 0.2, 0.4, 0.6, and 0.8 ml NH4OH/MeOH with LC/MS analysis. Note: prepare continue to follow the previous Phase 1 Phase 2 of 1 ppm STD and 0.5 ml 100 umM of sodium injection volume 10 ul. charts. Phase 2. procedure. of internal std. EDTA. TABLE 1 TABLE 2 1a 2a 3a 4a PREPARATION OF BUFFER SOLUTIONS Extraction 15 ml Ethyl 15 ml Ethyl 15 ml Ethyl 15 ml Ethyl Process data. 1M of Phosphate Buffer at Vortex, filter, Select the best END of Solvent acetate acetate acetate acetate 1M Citrate Buffer at pH 4.5 pH 7.4 and inject. extraction Phase 2 Buffer 0.5 ml 0.5 ml of 0.5 ml of 1 0.5 ml of solvent. Add 13.6 g of potassium Formic 1M citrate M triethylamine Add 19.2 g. of citric acid to 80 phosphate to 80 ml d.i. water. ml of d.i. water. Dropwise, Acid buffer pH phosphate Dropwise adjust pH to 7.4 with adjust pH to 4.5 with 1M 1M NaOH soution. Make to 4.5 pH 7.4 aqueous NaOH solution volume with water to 100 ml Proceed to Polytron 20 ml 20 ml 20 ml 20 ml 0.01M flowchart no.3 Solution 0.01M 0.01M 0.01M EDTA EDTA EDTA EDTA BuffersBuffers RuleRule thethe LL--LL ExtractionExtraction 1a 2a 3a 4a Extraction 15 ml Ethyl 15 ml Ethyl 15 ml Ethyl 15 ml Ethyl Solvent acetate acetate acetate acetate Buffer 0.5 ml 0.5 ml of 0.5 ml of 1 0.5 ml of Formic Acid 1M citrate M triethylamine buffer pH phosphate 4.5 pH 7.4 Polytron 20 ml 0.01M 20 ml 0.01M 20 ml 20 ml 0.01M Solution EDTA EDTA 0.01M EDTA EDTA SampleSample PreparationPreparation z Weigh 5 g of sample into 50 ml centrifuge tube z Add 30 ml of 50% acetonitrile with 10 mM EDTA, then add 0.5 mL of 1 M citrate buffer (pH 4.5) z Polytron 30 seconds z Sonicate sample for 20 minutes at 35 °C, vortex 30 seconds z Centrifuge for 4 minutes at 5000 rpm z Transfer supernatant to another 50 ml centrifuge tube.
Recommended publications
  • COMBINED LIST of Particularly Hazardous Substances
    COMBINED LIST of Particularly Hazardous Substances revised 2/4/2021 IARC list 1 are Carcinogenic to humans list compiled by Hector Acuna, UCSB IARC list Group 2A Probably carcinogenic to humans IARC list Group 2B Possibly carcinogenic to humans If any of the chemicals listed below are used in your research then complete a Standard Operating Procedure (SOP) for the product as described in the Chemical Hygiene Plan. Prop 65 known to cause cancer or reproductive toxicity Material(s) not on the list does not preclude one from completing an SOP. Other extremely toxic chemicals KNOWN Carcinogens from National Toxicology Program (NTP) or other high hazards will require the development of an SOP. Red= added in 2020 or status change Reasonably Anticipated NTP EPA Haz list COMBINED LIST of Particularly Hazardous Substances CAS Source from where the material is listed. 6,9-Methano-2,4,3-benzodioxathiepin, 6,7,8,9,10,10- hexachloro-1,5,5a,6,9,9a-hexahydro-, 3-oxide Acutely Toxic Methanimidamide, N,N-dimethyl-N'-[2-methyl-4-[[(methylamino)carbonyl]oxy]phenyl]- Acutely Toxic 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU) Prop 65 KNOWN Carcinogens NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) IARC list Group 2A Reasonably Anticipated NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) Prop 65 1-(o-Chlorophenyl)thiourea Acutely Toxic 1,1,1,2-Tetrachloroethane IARC list Group 2B 1,1,2,2-Tetrachloroethane Prop 65 IARC list Group 2B 1,1-Dichloro-2,2-bis(p -chloropheny)ethylene (DDE) Prop 65 1,1-Dichloroethane
    [Show full text]
  • Equimax & Eraquell Oral Gel for Horses
    Equimax & Eraquell Oral Gel for Horses Annual Wormer Pack [active ingredients: Ivermectin & Praziquantel] (POM-VPS) Revised AN Equimax Oral Gel for Horses January 2013 01009/2012 Eraquell Oral Gel for Horses December 2015 01163/2015 Page 1 of 15 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equimax Oral Gel for Horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram of Equimax contains Active substances Ivermectin ........................................................ 18.7 mg Praziquantel ..................................................... 140.3 mg Excipients Titanium dioxide (E171) ................................... 20 mg Propylene glycol ............................................... 731 mg For a full list of excipents, see section 6.1 3. PHARMACEUTICAL FORM Oral gel. 4. CLINICAL PARTICULARS 4.1 Target species Horses. 4.2 Indications for use, specifying the target species For the treatment of mixed cestode and nematode or arthropod infestations, due to adult and immature roundworms, lungworms, bots and tapeworms in horses: Nematodes Large-strongyle: Strongylus vulgaris (adult and arterial larvae) Strongylus edentatus (adult and L4 tissue larval stages) Strongylus equinus (adult) Triodontophorus spp. (adult) Small-strongyle: Cyathostomum: Cylicocyclus spp., Cylicostephanus spp., Cylicodontophorus spp., Gyalocephalus spp. (adult and non-inhibited mucosal larvae). Parascaris: Parascaris equorum (adult and larvae). Page 2 of 15 Oxyuris: Oxyuris equi (larvae). Trichostrongylus:Trichostrongylus
    [Show full text]
  • The Bhagirathi Cooperative Milk Producers' Union Limited
    The Bhagirathi Cooperative Milk Producers’ Union Limited TESTING PARAMETERS OF MILK & MILK PRODUCTS THAT SHOULD BE TESTED MICROBIOLOGICAL PARAMETER FOR PANEER 1] SPC(cfu/ ml) 2] Coliform (cfu/ ml) 3] E.Coli (cfu/ ml) 4] Salmonella (cfu/ 25gm) 5] Listeria monocytogenes (cfu/ gm) 6] Staphylococcus aureus (cfu/ gm) 7] Yeast & mould count (cfu/ gm) MICROBIOLOGICAL PARAMETER FOR DAHI 1] Coliform (cfu/ ml) 2] E.Coli (cfu/ ml) 3] Salmonella (cfu/ 25gm) 4] Listeria monocytogenes (cfu/ gm) 5] Staphylococcus aureus (cfu/ gm) 6] Yeast & mould count (cfu/ gm) 7] Anaerobic Spore count (cfu/ gm) MICROBIOLOGICAL PARAMETER IN FINISHED MILK THAT SHOULD BE TESTED 1] SPC(cfu/ ml) 2] Coliform (cfu/ ml) 3] Salmonella (cfu/ 25gm) 4] Listeria monocytogenes (cfu/ gm) The Bhagirathi Cooperative Milk Producers’ Union Limited LIST OF ANTIBIOTICS IN FINISHED MILK THAT SHOULD BE TESTED 1. Ampicillin 2. Cloxacillin 3. Colistin 4. Dihydrostreptomycin Streptomycin 5. Chlortetracycline/Oxytetracycline/Tetracycline 6. Lincomycin 7. Neomycin 8. Salinomycin 9. Spectinomycin 10. Sulphadiazine 11. Sulphathiazole Sodium 12. Trimethoprim 13. Sulfadiazine 14. Sulfanilamide 15. Sulfaguanidine 16. Zine Bacitracin (minimum 60lU/mg dried substance) 17. Amprolium 18. Apramycin 19. Ceftiofur 20. Cephapirine 21. Clopidol 22. Enrofloxacin 23. Ethopabate 24. Flavophospholipol (Flavomycin) 25. Monensin 26. Sulphaquinoxaline 27. Sulfadimidine 28. Tyvalosin Tartrate 29. Virginiamycin 30. Acepromazine 31. Albendazole 32. Amitraz 33. Aspirin 34. Buserelin 35. Butafosfane 36. Butaphosphan 37. Calcium Borogluconate 38. Calcium Magnesium Borogluconate 39. Carboprost tromethamine 40. Cefquinone Sulphate 41. Chloral hydrate 42. Closprostenol Sodium 43. Clenbutrol (Broncopulmin powder) 44. Diethylcarbarnazine 45. Dinitolmide 46. Doramectin The Bhagirathi Cooperative Milk Producers’ Union Limited LIST OF ANTIBIOTICS IN FINISHED MILK THAT SHOULD BE TESTED 47.
    [Show full text]
  • Summary of Product Characteristics 1. Name Of
    Revised: July 2018 AN: 02259/2017 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Paramectin Drench 0.8 mg/ml Oral Solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance: Ivermectin 0.8 mg/ml Excipients: Benzyl alcohol 30 ml/ml For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Oral solution A pale yellow clear liquid 4. CLINICAL PARTICULARS 4.1 Target species Sheep 4.2 Indications for use, specifying the target species Treatment and control of gastrointestinal nematodes, lungworms and nasal bots of sheep Gastrointestinal worms (adult and immature): Haemonchus contortus, Ostertagia circumcincta, Trichostrongylus spp, Cooperia spp, Nematodirus spp including N. battus, Strongyloides papillosus, Oesophagostomum spp, and adult Chabertia ovina Inhibited larval stages and benzimidazole resistant strains of H. contortus and Ostertagia circumcincta are also controlled. Lungworms (adult and immature): Dictyocaulus filaria Nasal bot (all larval stages): Oestrus ovis 4.3 Contraindications The product has been formulated specifically for use in sheep. It should not be used in other species, as severe adverse reactions, including fatalities in dogs, may occur. Page 1 of 5 Revised: July 2018 AN: 02259/2017 Do not use in cases of hypersensitivity to the active substances or to any of the excipients. The product is not for intravenous or intramuscular use. Do not use in sheep producing milk for human consumption. 4.4 Special warnings for each target species Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy: Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
    [Show full text]
  • Organophosphate Pesticide) in Soil by Bacterial Isolates
    Journal of Natural Sciences Research www.iiste.org ISSN 2224-3186 (Paper) ISSN 2225-0921 (Online) Vol.3, No.8, 2013 Biodegradation of Dichlorovos (Organophosphate Pesticide) in Soil by Bacterial Isolates S. E. AGARRY, O. A. OLU-AROTIOWA, *M. O. AREMU AND L. A. JIMODA Biochemical Engineering and Environmental Biotechnology Research Laboratory, Department of Chemical Engineering, Ladoke Akintola University of Technology, Ogbomoso, Nigeria *Corresponding Author: [email protected] Abstract Excessive and continuous dispersion of pesticides which are toxic heterogeneous compound in the environment results in environmental pollution with ecological effects that require remediation. This study investigated the potential of microbial isolates to biodegrade or cleans up agricultural soil artificially contaminated with Dichlorvos (2, 2-dichlorovinyldimethylphosphate) pesticide. A bacterial consortium which degraded Dichlorvos pesticide was isolated from agricultural soil using pour plate method. This consortium was composed of four pure strains which were characterized based on their morphological and biochemical characteristics. The strains were presumptively identifies as Proteus vulgaris , Vibrio sp., Serratia sp. and Acinetobacte r sp. The consortium and the four bacteria were evaluated in order to discover their ability to biodegrade Dichlorvos pesticide in medium supplied with different nutrients (NH 4NO 3, KH 2PO 4 and NPK (20:10:10) fertilizer). The results showed that the bacterial consortium and the four bacteria isolates were able to grow in nutrient medium containing Dichlorvos as the only carbon source. Moreover, the bacterial consortium was able to remove greater amount of DDP in soil amended with inorganic fertilizer (NPK) than those amended with NH 4NO 3 and KH 2PO 4, respectively.
    [Show full text]
  • Etude Rétrospective Des Déclarations D'effets Indésirables Graves Lors D
    Etude rétrospective des déclarations d’effets indésirables graves lors d’utilisation d’antiparasitaires externes chez le chat et le chien Kim Schumacher To cite this version: Kim Schumacher. Etude rétrospective des déclarations d’effets indésirables graves lors d’utilisation d’antiparasitaires externes chez le chat et le chien. Médecine vétérinaire et santé animale. Université Paris-Est Créteil Val de Marne (UPEC); École nationale vétérinaire d’Alfort, 2016. Français. tel- 01874183 HAL Id: tel-01874183 https://tel.archives-ouvertes.fr/tel-01874183 Submitted on 14 Sep 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. ÉCOLE NATIONALE VÉTÉRINAIRE D’ALFORT Année 2016 ÉTUDE RÉTROSPECTIVE DES DÉCLARATIONS D’EFFETS INDÉSIRABLES GRAVES LORS D’UTILISATION D’ANTIPARASITAIRES EXTERNES CHEZ LE CHAT ET LE CHIEN THÈSE Pour le DOCTORAT VÉTÉRINAIRE Présentée et soutenue publiquement devant LA FACULTÉ DE MÉDECINE DE CRÉTEIL le…………… par Kim Charlotte Amédée SCHUHMACHER Née le 4 décembre 1991 à Vélizy-Villacoublay (Yvelines) JURY Président : Pr. Professeur à la Faculté de Médecine de CRÉTEIL Membres Directeur : M. PERROT Sébastien Maître de conférences en Pharmacologie à l’ENVA Assesseur : Mme DARMON Céline Maître de conférences en Parasitologie à l’ENVA REMERCIEMENTS Au Professeur de la Faculté de médecine de Créteil, Qui nous a fait l’honneur d’accepter la présidence de notre jury de thèse, Hommage respectueux.
    [Show full text]
  • Parasiticides: Fenbendazole, Ivermectin, Moxidectin Livestock
    Parasiticides: Fenbendazole, Ivermectin, Moxidectin Livestock 1 Identification of Petitioned Substance* 2 3 Chemical Names: 48 Ivermectin: Heart Guard, Sklice, Stomectol, 4 Moxidectin:(1'R,2R,4Z,4'S,5S,6S,8'R,10'E,13'R,14'E 49 Ivomec, Mectizan, Ivexterm, Scabo 6 5 ,16'E,20'R,21'R,24'S)-21',24'-Dihydroxy-4 50 Thiabendazole: Mintezol, Tresaderm, Arbotect 6 (methoxyimino)-5,11',13',22'-tetramethyl-6-[(2E)- 51 Albendazole: Albenza 7 4-methyl-2-penten-2-yl]-3,4,5,6-tetrahydro-2'H- 52 Levamisole: Ergamisol 8 spiro[pyran-2,6'-[3,7,1 9]trioxatetracyclo 53 Morantel tartrate: Rumatel 9 [15.6.1.14,8.020,24] pentacosa[10,14,16,22] tetraen]- 54 Pyrantel: Banminth, Antiminth, Cobantril 10 2'-one; (2aE, 4E,5’R,6R,6’S,8E,11R,13S,- 55 Doramectin: Dectomax 11 15S,17aR,20R,20aR,20bS)-6’-[(E)-1,2-Dimethyl-1- 56 Eprinomectin: Ivomec, Longrange 12 butenyl]-5’,6,6’,7,10,11,14,15,17a,20,20a,20b- 57 Piperazine: Wazine, Pig Wormer 13 dodecahydro-20,20b-dihydroxy-5’6,8,19-tetra- 58 14 methylspiro[11,15-methano-2H,13H,17H- CAS Numbers: 113507-06-5; 15 furo[4,3,2-pq][2,6]benzodioxacylooctadecin-13,2’- Moxidectin: 16 [2H]pyrano]-4’,17(3’H)-dione,4’-(E)-(O- Fenbendazole: 43210-67-9; 70288-86-7 17 methyloxime) Ivermectin: 59 Thiabendazole: 148-79-8 18 Fenbendazole: methyl N-(6-phenylsulfanyl-1H- 60 Albendazole: 54965-21-8 19 benzimidazol-2-yl) carbamate 61 Levamisole: 14769-72-4 20 Ivermectin: 22,23-dihydroavermectin B1a +22,23- 21 dihydroavermectin B1b 62 Morantel tartrate: 26155-31-7 63 Pyrantel: 22204-24-6 22 Thiabendazole: 4-(1H-1,3-benzodiazol-2-yl)-1,3- 23 thiazole
    [Show full text]
  • Poster Munoz Et Al Avm 4 Nt
    ANTHELMINTIC AVERMECTINS FOR THE TREATMENT OF NON- TUBERCULOSIS MYCOBACTERIA INFECTIONS IN CYSTIC FIBROSIS Lara Muñoz Muñoz1,2,*, Charles J. Thompson3, and Santiago Ramón-García2,3,4,* 1 Clinical University Hospital Lozano Blesa, Zaragoza, Spain 2 Department of Microbiology, Preventive Medicine and Public Health, Faculty of Medicine, University of Zaragoza, Spain; 3 Department of Microbiology and Immunology, Centre for Tuberculosis Research, University of British Columbia, Canada; 4 Research & Development Agency of Aragon (ARAID) Foundation, Spain. *Email: [email protected] and [email protected] INTRODUCTION Pulmonary disease caused by non-tuberculosis mycobacteria (NTM) has emerged as a major threat to the health of individuals with cystic fibrosis (CF). The NTM most commonly identified are Mycobacterium abscessus (MABSC) and Mycobacterium avium (MAC) complexes. MABSC includes 3 species M. abscessus sb. abscessus, M. abscessus sb. bolletii and M. abscessus sb. masiliense. Ivermectin Selamectin Avermectins are a family of macrocyclic lactone compounds used as anthelmintics. Although inactive against Gram-positive and Gram-negative bacteria, they have demonstrated in vitro activity against mycobacterial species, including Mycobacterium tuberculosis, Mycobacterium ulcerans and Mycobacteriym marinum (PMID: 26270480 & 23165468). Milbemycin Doramectin OBJECTIVE oxime To evaluate the in vitro activity of the avermectins against MABSC and MAC. CONCLUSIONS The avermectins comprise clinically approved drugs (i.e. ivermectin) and are extensively
    [Show full text]
  • Tutorial Article a Review of the Use of Moxidectin in Horses J
    EVE 08-054 Schumacher 17/9/08 09:34 Page 2 546 EQUINE VETERINARY EDUCATION / AE / october 2008 Tutorial Article A review of the use of moxidectin in horses J. SCHUMACHER* AND J. TAINTOR Department of Clinical Sciences, J.T. Vaughan Teaching Hospital, College of Veterinary Medicine, Auburn University, Alabama, 36849-5522, USA. Keywords: horse; moxidectin; ivermectin; cyathostomins; ascarids; ectoparasites; resistance Summary which are produced naturally from soil-dwelling Streptomyces microorganisms, are divided into 2 classes of anti-parasitic Moxidectin has broad-spectrum anti-nematodal and drugs, the avermectins and the milbemycins. The first anti-arthropodal activities in the horse but is not macrocyclic lactone introduced to the equine market was the effective against tapeworms or flukes. Moxidectin and avermectin, ivermectin, which was introduced in 1981. That ivermectin have the same efficacy against internal, adult drug revolutionised control of endoparasites and ectoparasites parasites of horses. Moxidectin, however, is highly in many different species because of its relative safety and effective in eliminating encysted and hypobiotic larval efficacy against most economically important parasitic stages of cyathostomins, whereas ivermectin is not. diseases. Since the introduction of ivermectin, other Treatment of horses with moxidectin results in an egg- macrocyclic lactones have been introduced, including reappearance period (ERP) of 15–24 weeks. Because of albamectin, eprinomectin, doramectin, selamectin, moxidectin its long ERP, moxidectin is labelled to be used at and milbemycin A3/A4. Ivermectin, albamectin and 12 week intervals. Moxidectin may provide protection moxidectin are marketed for use in horses. against infection by ingested cyathostomin larvae for 2–3 weeks after it is administered.
    [Show full text]
  • Sheet1 Page 1 a Abamectin Acetazolamide Sodium Adenosine-5-Monophosphate Aklomide Albendazole Alfaxalone Aloe Vera Alphadolone A
    Sheet1 A Abamectin Acetazolamide sodium Adenosine-5-monophosphate Aklomide Albendazole Alfaxalone Aloe vera Alphadolone Acetate Alpha-galactosidase Altrenogest Amikacin and its salts Aminopentamide Aminopyridine Amitraz Amoxicillin Amphomycin Amphotericin B Ampicillin Amprolium Anethole Apramycin Asiaticoside Atipamezole Avoparcin Azaperone B Bambermycin Bemegride Benazepril Benzathine cloxacillin Benzoyl Peroxide Benzydamine Bephenium Bephenium Hydroxynaphthoate Betamethasone Boldenone undecylenate Boswellin Bromelain Bromhexine 2-Bromo-2-nitropan-1, 3 diol Bunamidine Buquinolate Butamisole Butonate Butorphanol Page 1 Sheet1 C Calcium glucoheptonate (calcium glucoheptogluconate) Calcium levulinate Cambendazole Caprylic/Capric Acid Monoesters Carbadox Carbomycin Carfentanil Carnidazole Carnitine Carprofen Cefadroxil Ceftiofur sodium Centella asiatica Cephaloridine Cephapirin Chlorine dioxide Chlormadinone acetate Chlorophene Chlorothiazide Chlorpromazine HCl Choline Salicylate Chondroitin sulfate Clazuril Clenbuterol Clindamycin Clomipramine Clopidol Cloprostenol Clotrimazole Cloxacillin Colistin sulfate Copper calcium edetate Copper glycinate Coumaphos Cromolyn sodium Crystalline Hydroxycobalamin Cyclizine Cyclosporin A Cyprenorphine HCl Cythioate D Decoquinate Demeclocycline (Demethylchlortetracycline) Page 2 Sheet1 Deslorelin Desoxycorticosterone Pivalate Detomidine Diaveridine Dichlorvos Diclazuril Dicloxacillin Didecyl dimethyl ammonium chloride Diethanolamine Diethylcarbamazine Dihydrochlorothiazide Diidohydroxyquin Dimethylglycine
    [Show full text]
  • Antiparasitic Non-Aqueous Formulation Containing an Avermectin Or Milbemycin
    Patentamt JJEuropaisch.es European Patent Office @ Publication number: O 1 46 414 ^2 Office europeen des brevets @ EUROPEAN PATENT APPLICATION ® Application number: 84309044.0 ® Int. CI ": A 61 K 31/71, A 61 K 47/00 <g) Date of filing: 21 .12.84 ® Priority: 22.12.83 US 564140 @ Applicant: MERCK & CO. INC., 126, East Lincoln Avenue P.O. Box 2000, Rahway New Jersey 07065 (US) ® ® Date of publication of application: 26.06.85 'nvenjor: ^'l!'8/!18' *'ame8 Coventry Drive, Freehold Bullnflri A5/9fi NOW JOfSGy (US) " Inventor: Nesbltt, Russell U., 292 Miller Avenue, Somerville New Jersey 08876 (US) @ Designated Contracting States : AT BE CH DE FR GB IT @ Representative : Crampton, Keith John Allen et al, D LI LU NL SE YOUNG & C0 10 Staple Inn, London WC1V7RD (GB) @ Antiparasitic non-aqueous formulation containing an avermectin or milbemycin. Ivermectin, an antiparasitic agent which is insoluble and unstable in water, and other avermectin and milbemycin com- pounds, are formulated in glycerol formal and propylene glycol or in water and propylene glycol. These liquid formulations are suitable for parenteral administration for the treatment of parasitic infections and demonstrate improved efficacy and a broadened spectrum over previous formulations. The present invention concerns the preparation of avermectin and milbemycin parenteral formulations. More particularly, but not exclusively, the avermectin is ivermectin, an anthelmintic agent. The avermectin family, of which ivermectin is a member, is a series of new and very potent antiparasitic agents which are useful against a broad spectrum of endoparasites and ectoparasites in mammals as well as having agricultural uses against various parasites found in and on crops and in soil.
    [Show full text]
  • Recommended Classification of Pesticides by Hazard and Guidelines to Classification 2019 Theinternational Programme on Chemical Safety (IPCS) Was Established in 1980
    The WHO Recommended Classi cation of Pesticides by Hazard and Guidelines to Classi cation 2019 cation Hazard of Pesticides by and Guidelines to Classi The WHO Recommended Classi The WHO Recommended Classi cation of Pesticides by Hazard and Guidelines to Classi cation 2019 The WHO Recommended Classification of Pesticides by Hazard and Guidelines to Classification 2019 TheInternational Programme on Chemical Safety (IPCS) was established in 1980. The overall objectives of the IPCS are to establish the scientific basis for assessment of the risk to human health and the environment from exposure to chemicals, through international peer review processes, as a prerequisite for the promotion of chemical safety, and to provide technical assistance in strengthening national capacities for the sound management of chemicals. This publication was developed in the IOMC context. The contents do not necessarily reflect the views or stated policies of individual IOMC Participating Organizations. The Inter-Organization Programme for the Sound Management of Chemicals (IOMC) was established in 1995 following recommendations made by the 1992 UN Conference on Environment and Development to strengthen cooperation and increase international coordination in the field of chemical safety. The Participating Organizations are: FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD. The purpose of the IOMC is to promote coordination of the policies and activities pursued by the Participating Organizations, jointly or separately, to achieve the sound management of chemicals in relation to human health and the environment. WHO recommended classification of pesticides by hazard and guidelines to classification, 2019 edition ISBN 978-92-4-000566-2 (electronic version) ISBN 978-92-4-000567-9 (print version) ISSN 1684-1042 © World Health Organization 2020 Some rights reserved.
    [Show full text]